Stock Price Quote

GLAXOSMITHKLINE PHARMACEUTICALS LTD.

NSE : GLAXOBSE : 500660ISIN CODE : INE159A01016Industry : Pharmaceuticals & DrugsHouse : Glaxosmithkline - MNC
BSE2699.1071.45 (+2.72 %)
PREV CLOSE ( ) 2627.65
OPEN PRICE ( ) 2659.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 31540
TODAY'S LOW / HIGH ( )2628.20 2708.95
52 WK LOW / HIGH ( )1376.5 2708.95
NSE2700.7075.05 (+2.86 %)
PREV CLOSE( ) 2625.65
OPEN PRICE ( ) 2633.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 2700.70 (338)
VOLUME 181775
TODAY'S LOW / HIGH( ) 2630.00 2709.25
52 WK LOW / HIGH ( )1377.25 2709.25
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 13-11 1924
Management Info
R S Karnad - Chairman Bhushan Akshikar - Managing Director
Registered Office

Address Gsk House, Dr. Annie Besant Road,Worli,,
Mumbai,
Maharashtra-400030

Phone 022-24959595

Email askus@gsk.com / in.investorquery@gsk.com

Website www.gsk-india.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

12Jun GlaxoSmithKline Pharmaceuticals infor
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
11Jun GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
08May GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
07May GlaxoSmithKline Pharmaceuticals infor
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..
24Apr GlaxoSmithKline Pharmaceuticals inform
Pursuant to Regulation 39 and other application regulations of SEBI (Lis..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit1930.85846.90000000001
Gross Profit 2687.1 8090.40000000001
Operating Profit 2851.810241.3
Net Sales 9108.734072.5

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  6588.50 (3.56%)
M.Cap ( in Cr)8452.97
Divi's Lab (BSE)
peergroup  4593.00 (3.24%)
M.Cap ( in Cr)121929.72
Fredun Pharma (BSE)
peergroup  918.15 (15.49%)
M.Cap ( in Cr)433.52
Mercury Laboratories (BSE)
peergroup  935.80 (7.43%)
M.Cap ( in Cr)112.30
Abbott India (BSE)
peergroup  27612.80 (0.20%)
M.Cap ( in Cr)58675.27

Shareholding Pattern

PROMOTERS 75%
MUTUAL FUNDS/UTI 4.51%
FI/BANKS/INSURANCE 3.27%
NON-INSTITUTION 13.62%
GOVERNMENT 0%
FII 0%

About Glaxosmithkline Pharmaceuticals Ltd.

Glaxosmithkline Pharmaceuticals Ltd. was incorporated in the year 1924. Its today's share price is 2699.1. Its current market capitalisation stands at Rs 45724.38 Cr. In the latest quarter, company has reported Gross Sales of Rs. 37381.57 Cr and Total Income of Rs.35307.26 Cr. The company's management includes Manu Anand, Juby Chandy, Bhushan Akshikar, S Williams, R S Karnad, D Sundaram, PV Bhide, A N Roy, S Maheshwari, Ajay Nadkarni.

It is listed on the BSE with a BSE Code of 500660 , NSE with an NSE Symbol of GLAXO and ISIN of INE159A01016. It's Registered office is at Gsk House, Dr. Annie Besant Road,Worli,Mumbai-400030, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells LLP, Lovelock & Lewes, Price Waterhouse & Co, Price Waterhouse & Co Bangalore LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.